A seven day run of daily weigh-ins on tirzepatide, tracking how the scale moves from one morning to the next.
Recap by typeshit. Full story at The Weight Of It.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Labroots reports Lilly is moving against unauthorized sellers of retatrutide, an obesity drug that has not yet won approval.
Lilly says it has reported over 14,000 listings in more than 100 countries and wants platforms, payment firms and shippers to cut off sales of the unapproved drug.
Loading…